Nyrada is a pre-clinical stage, drug development company specialising in the development of novel small molecule drugs pertaining to the underlying pathological processes involved in cardiovascular, neurodegenerative and chronic inflammatory diseases.
The Company’s vision is to become a high growth bio-pharmaceutical company specialising in drug discovery and early stage drug development, based mainly around the benzopyran molecular scaffold and focusing on areas of substantial unmet clinical need, where few if any, effective or well-tolerated therapies exist.
The Company has four current drug development programs:
- Cardiovascular: a PCSK9 inhibitor for the treatment of high blood LDL-cholesterol levels in patients poorly responsive to or unable to take statin drugs
- Neuroprotection: a neuroprotectant drug to reduce the impact of long-term disability in patients with ischaemic stroke and traumatic brain injury
- Inflammation/pain: a drug to treat pain associated with peripheral nerve damage, and
- Inflammation/autoimmunity: a drug to treat autoimmune diseases such as psoriasis.